(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback